2012 Fiscal Year Final Research Report
Association between genetic polymorphisms of drug-metabolizingenzymes and factors of liver cancer
| Project/Area Number |
22501059
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cancer epidemiology and prevention
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KURATA Norimitsu 昭和大学, 教養部, 教授 (80231299)
NISHIMURA Yuki 昭和大学, 医学部, 講師 (40276572)
IWASE Mariko 昭和大学, 医学部, 助教 (70424273)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | CYP2C19 / 肝臓癌 / 遺伝子多型 / サイトカイン / 転移 |
|---|
| Research Abstract |
This study was conducted to clarify the association between drug-metabolizing enzyme CYP2C19 gene mutation and liver cancer susceptibility. 21 liver and blood samples were donated from Japanese liver cancer patients who received partial hepatectomy. The results indicated that the gene mutation found in high frequency in metastatic liver cancer patients occur congenitally rather than arise in peripheral tumor site acquired by cancer condition.CYP2C19 activity decreased in all samples and the degree was associated with changes in several cytokines, but did not correlate with the genotype of the enzyme. For the prevention of metastasis and for the proper treatment of liver cancer, further studies elucidating the mechanisms and significance of the results obtained and clarifying the role of CYP2C19 in cancer patients are needed.
|
